


# *Our pipeline*



**Kazuaki Ikeya**

**Corporate Officer, General Manager**

**Strategic Product Planning Dept.**

# Focused Therapeutic Areas

- **Franchise I: Life style-related diseases**
- **Franchise II :Oncology & Urologic diseases**
- **Franchise III: Central nervous system diseases**
- **Franchise IV :Gastroenterology diseases LCM**

# Franchise I: Life style-related disease(1)

Second half in FY04

Projects	Indications/formulations	Ph	Ph	NDA	Approval
<b>TCV-116</b>	<b>Chronic heart failure (U.S.)</b>				→ ○
<b>TCV-116</b>	<b>Chronic heart failure (EU)</b>				⋯→
<b>AD-4833MET</b>	<b>Fixed Combination drug of ACTOS/Metformin (U.S.)</b>				⋯→
<b>AD-4833MET</b>	<b>Fixed Combination drug of ACTOS/Metformin (EU)</b>				→
<b>TCV-116</b>	Chronic heart failure (Jpn)				
<b>TCV-116</b>	Fixed combination with diuretic (Jpn)				
<b>TAK-475</b>	<b>Hyperlipidemia (U.S.,EU)</b>				→
<b>TCV-116 DIRECT</b>	Diabetic Retinopathy (EU)				
<b>TCV-116</b>	High dose (Jpn)				

→ Stage up in 4Q in FY04

⋯→ Stage up in 3Q in FY04

Projects of P-II or later are listed

3

# Franchise I: Life style-related disease (2)

Second half in FY04

Projects	Indications/formulations	Ph	Ph	NDA	Approval
AD-4833	Delay in progression of Atherosclerosis (U.S.)				
AD-4833 PROactive	Secondary prevention of macrovascular event (EU)				
AO-128	Impaired Glucose Tolerance (Jpn)				
<b>TAK-128</b>	<b>Diabetic neuropathy (U.S.)</b> →				
TAK-654	Diabetes mellitus (Jpn,U.S.,EU,)				
TAK-428	Diabetic neuropathy (U.S.,EU)				
TCV-116	Diabetic nephropathy (Jpn)				
TAK-536	Hypertension (U.S., EU)				
LY333531	Diabetic maculopathy (Jpn)				

→ Stage up in 4Q in FY04

.....▶ Stage up in 3Q in FY04

Projects of P-II or later are listed

# Franchise II: Oncology & Urologic disease

Second half in FY04

Projects	Indications/formulations	Ph	Ph	NDA	Approval
<b>MH-15E</b>	<b>Morphine hydrochloride for extradural administration (Jpn)</b>			.....▶	
<b>TAK-453-SR</b>	Morphine hydrochloride sustained release capsule (Jpn)				
<b>TAP-144SR(3M)</b>	Premenopausal breast cancer (Jpn)				
<b>TAP-144SR(6M)</b>	Prostate cancer (U.S., EU)				
<b>TAK-013</b>	Endometriosis, uterine fibroid (U.S., EU)				
<b>TAK-013</b>	<b>Endometriosis, uterine fibroid (Jpn)▶</b>				
<b>TAK-802</b>	Hypoactive bladder (Jpn)				

.....▶ **Stage up in 3Q in FY04**

Projects of P-II or later are listed

# Franchise III: Central nervous system disease

## Bone / joint disease

Second half in FY04

Projects	Indications/formulations	Ph	Ph	NDA	Approval
TAK-375	Insomnia (U.S.)				
TAK-375	Insomnia (EU)				
TAK-375	<b>Insomnia (Jpn)</b>	.....▶			
TAK-375	Circadian rhythm sleep disorder (U.S.)	○			


NE-58095 (Benet)	<b>Once-a-week formulation (Jpn)</b>		.....▶		
TAK-715	Rheumatoid arthritis (U.S.,EU)				


.....▶ **Stage up in 3Q in FY04**

Projects of P-II or later are listed

# Franchise IV: Gastroenterology disease LCM

Second half in FY04

Projects	Indications/formulations	Ph	Ph	NDA	Approval
<b>SPI-0211(Lubiprostone)</b>	<b>Chronic idiopathic constipation</b>				
<b>AG-1749</b>	S-GERD (Jpn)				
<b>AG-1749</b>	Injectable formulation (Jpn)				

<b>TAK-201</b>	<b>Cryptomeria pollinosis</b> 				
<b>TMR</b>	Double combination of vaccine against measles and rubella				


 **Stage up in 4Q in FY04**

Projects of P-II or later are listed

 **Stage up in 3Q in FY04**

# TAK-375

## Phase III study for the treatment of chronic insomnia in elderly patients



- Ramelteon 4 or 8 mg statistically reduced time to fall asleep and increased total sleep time
- No rebound insomnia or withdrawal effects were observed after discontinuation of Ramelteon treatment.
- Ramelteon was well tolerated in this elderly patients population

Source: American Geriatric Society 2005

# In-licensed products

<b>TAK-128</b>	<b>R851</b>	<b>TAK-363</b>
Drug for Diabetic neuropathy	Drug for HPV (Human Papilloma Virus ) infection*.	Drug for frequent urination / urinary incontinence
P-II (U.S.)	P-I (U.S.)	under preparation for clinical trial
improving function of neurotransmitter by accelerating myelin formation.	stimulating human body's immune system to attack virus-infected cells and tumor cells.	suppressing abnormal signs from bladder to central nervous system in OAB
Licensed from Mitsubishi Pharma Corporation	Licensed from 3M	Licensed from Toray

\*HPV infection is consider to be risk factor of cervical cancer.

The products that were licensed or progressed in the second half of FY2004 are listed.

# Takeda San Diego, Inc. (former Syrrx)



## **Technology**

High-throughput X-ray crystallography capabilities to determine the three dimensional structures of drug targets.

## **IND Engine**

Creation of molecular for IND based on its technology

**Foundation & location : 1999, San Diego, California, USA**

**Focused category : Cancer ,Metabolic diseases including diabetes**

**Pipeline : DPP-IV inhibitor ( Ph II:alliance with PPD )**

**11 -HSD-1 inhibitor, HDAC inhibitor( pre-clinical :alliance with Roche )**

**Aurora kinase inhibitor ( pre-clinical, cancer )**

**Employee : 92 ( 38 has PhD degree among 75 researchers)**

## Establishment of TSD (Takeda San Diego) : Benefits

### ➤ *Complement to in-house research projects*

Production of early stage pipeline as **IND Engine**

### ➤ *Acceleration of in-house research projects and increase success rate of the projects*

Application of the sophisticated technology of TSD to in-house projects

### ➤ *Access to pipeline in diabetes and oncology*

DPP-IV inhibitor, SYR-322 , SYR-619


### ➤ *Establishment of research base in the US*

The first step to build global research network

# Multi-Cylinder IND Engine Model

for superior drug discovery productivity

Healthy Competition / Collaboration among IND engine cylinders



# Product Strategy Team (PST)

- **PST** consisting of members from Strategic Product Planning Dept. and related departments has started in April 2005.
- **PST** makes a plan maximizing a product value in global view point and monitor its action plan.

